{"nctId":"NCT00979901","briefTitle":"Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)","startDateStruct":{"date":"2000-03"},"conditions":["Seasonal Allergic Rhinitis"],"count":1577,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: montelukast"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: loratadine"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: placebo"]},{"label":"4","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: montelukast/loratadine"]}],"interventions":[{"name":"Comparator: montelukast","otherNames":[]},{"name":"Comparator: loratadine","otherNames":[]},{"name":"Comparator: placebo","otherNames":[]},{"name":"Comparator: montelukast/loratadine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has a documented history of seasonal allergic rhinitis symptoms that flare up during the study season\n* Patient is a nonsmoker and has been a nonsmoker for at least 1 year\n* Patient is in good general health\n\nExclusion Criteria:\n\n* Patient is hospitalized\n* Patient is a woman who is less than 8 weeks postpartum or is breast-feeding\n* Patient intends to move or vacation away during the study\n* Patient has had any major surgery within 4 weeks of study start\n* Patient is a current or past abuser of alcohol or illicit drugs\n* Patient has been treated in an emergency room for asthma in the past month\n* Patient had an upper respiratory infection with in 3 weeks prior to study start","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"85 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Daytime Nasal Symptoms Score Over 2 Weeks","description":"Mean change from baseline in Daytime Nasal Symptoms score.\n\nPatients were asked to rate each of the 4 nasal symptoms of Congestion, Rhinorrhea, Itching, and Sneezing daily\n\non a 4-point scale. The average of the 4 individual nasal symptoms scores was reported as the Daytime Nasal\n\nSymptoms Score. Scores were measured as 0 (best) to 3 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":null},{"groupId":"OG001","value":"-0.37","spread":null},{"groupId":"OG002","value":"-0.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Nighttime Symptoms Score Over 2 Weeks","description":"Mean change from baseline in Nighttime Symptoms Score.\n\nPatients were asked to rate each symptom daily on a 4-point scale, and the combined score of Nasal Congestion Upon Awakening, Difficulty Going to Sleep, and Nighttime Awakenings was reported as the Nighttime Symptoms Score. Scores were measured as 0 (best) to 3 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":null},{"groupId":"OG001","value":"-0.27","spread":null},{"groupId":"OG002","value":"-0.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Daytime Eye Symptoms Score Over 2 Weeks","description":"Mean change from baseline in Daytime Eye Symptoms scores.\n\nPatients were asked to rate each of the 4 eye symptoms of tearing, itchy, red, and puffy eyes daily on a 4-point scale. The average of the 4 individual eye symptoms scores was reported as the Daytime Eye Symptoms Score. Scores were measured as 0 (best) to 3 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":null},{"groupId":"OG001","value":"-0.26","spread":null},{"groupId":"OG002","value":"-0.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Global Evaluation of Allergic Rhinitis at Week 2","description":"An evaluation by the patient, administered at the last visit (or\n\nupon discontinuation) using a 7-point scale, of the change in symptoms as compared to the beginning of the\n\nstudy. Scores were measured as 0 (best) to 6 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":null},{"groupId":"OG001","value":"2.20","spread":null},{"groupId":"OG002","value":"2.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Global Evaluation of Allergic Rhinitis at Week 2","description":"An evaluation by the physician, administered at the last visit (or upon discontinuation) using a 7-point scale, of the change in symptoms as compared to the beginning of the study. Scores were measured as 0 (best) to 6 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","spread":null},{"groupId":"OG001","value":"2.23","spread":null},{"groupId":"OG002","value":"2.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Rhinoconjunctivitis Quality-of-life Questionnaire (RQLQ) Overall Score at Week 2","description":"Patients completed the validated, self-administered RQLQ, which included 28 items on a 7-point scale across 7 domains: activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional. Scores for each domain were averaged, then scores for the 7 domains were averaged for the overall score. Scores were measured as 0 (best) to 6 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":null},{"groupId":"OG001","value":"-0.89","spread":null},{"groupId":"OG002","value":"-0.99","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":352},"commonTop":[]}}}